Enora Laas
Overview
Explore the profile of Enora Laas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
689
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Clinico-pathological factors predicting pathological response in early triple-negative breast cancer
Helal C, Djerroudi L, Ramtohul T, Laas E, Vincent-Salomon A, Jin M, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):15.
PMID: 39948122
Pathological complete response (pCR) after neoadjuvant chemoimmunotherapy (NACi) is associated with improved patient outcomes in early triple-negative breast cancer (TNBC). This study aimed to identify factors associated with pCR after...
2.
Ceccato V, Wallaert L, Michel S, Gaillard T, Girard N, Darrigues L, et al.
Sci Rep
. 2025 Feb;
15(1):5002.
PMID: 39930014
Wire guided localization is widely used as the standard method of pre-operative localization of breast lesions. The aim was to assess outcomes following the introduction of a novel non-wire guided,...
3.
Malhaire C, Umay O, Cockenpot V, Selhane F, Ramtohul T, Reyal F, et al.
Eur Radiol
. 2025 Feb;
PMID: 39920303
Objectives: To predict axillary node residual disease in women treated for node-positive breast cancer (BC) by neoadjuvant therapy (NAT), using breast BI-RADS MRI features and axillary ultrasound at baseline. Material...
4.
Jochum F, Doll M, Hamy A, Donval L, Gougis P, Dumas E, et al.
EClinicalMedicine
. 2025 Jan;
80:103053.
PMID: 39867969
Background: Randomized clinical trials (RCTs) are fundamental to evidence-based medicine, but their real-world impact on clinical practice often remains unmonitored. Leveraging large-scale real-world data can enable systematic monitoring of RCT...
5.
Laas E, Dumas E, Hamy A, Gaillard T, Gougis P, Reyal F, et al.
Eur J Surg Oncol
. 2024 Nov;
51(1):109373.
PMID: 39549387
Background: Suboptimal treatment delays is known to impact prognosis of patients with cancer but optimal timing in specific subgroups remains poorly studied. This study aimed to analyze treatment delays in...
6.
Peyrottes A, Masson-Lecomte A, Mongiat-Artus P, Nourieh M, Sirab N, Reyal F, et al.
Fr J Urol
. 2024 Sep;
34(13):102751.
PMID: 39305999
Introduction: Renal cell carcinoma (RCC) and breast carcinoma (BC) are frequent tumours, yet their co-occurrence in the same patient is a unique scenario. Few studies explored the characteristics of such...
7.
Ramtohul T, Lepagney V, Bonneau C, Jin M, Menet E, Sauge J, et al.
Radiology
. 2024 Sep;
312(3):e240575.
PMID: 39225608
Background Neoadjuvant chemoimmunotherapy (NACI) has significantly increased the rate of pathologic complete response (pCR) in patients with early-stage triple-negative breast cancer (TNBC), although predictors of response to this regimen have...
8.
Jochum F, Hamy A, Gougis P, Dumas E, Grandal B, Sauzey M, et al.
Br J Surg
. 2024 Aug;
111(8).
PMID: 39150046
Background: The main objective of this study was to undertake an exhaustive investigation of sex-related differences in cancer surgery. Methods: This observational study used data from the French national health...
9.
Jochum F, Dumas E, Gougis P, Hamy A, Querleu D, Lecointre L, et al.
Am J Obstet Gynecol
. 2024 Aug;
232(2):194.e1-194.e11.
PMID: 39111517
Background: The effect of primary cytoreductive surgery vs interval cytoreductive surgery on International Federation of Gynecology and Obstetrics stage IV ovarian cancer outcomes remains uncertain and may vary depending on...
10.
Cyrta J, Brillet R, Laas E, Just P, Andrianteranagna M, Leary A, et al.
Am J Surg Pathol
. 2024 Aug;
48(10):1335-1338.
PMID: 39092991
No abstract available.